Global COVID-19 Saliva Screening Test Market Report 2021-2023 – Increasing Product Approvals by Regulatory Agencies & Paradigm Shift Toward Point-of-Care Testing

DUBLIN, Sept. 8, 2021 /PRNewswire/ — The «Global COVID-19 Saliva Screening Test Potential Market 2021-2023» report has been added to…

DUBLIN, Sept. 8, 2021 /PRNewswire/ — The «Global COVID-19 Saliva Screening Test Potential Market 2021-2023» report has been added to ResearchAndMarkets.com’s offering.

Research and Markets Logo

The global COVID-19 saliva screening test potential market size is expected to reach USD 3,406.2 billion by 2023.

The market is estimated to expand at a CAGR of 4.8% from 2021 to 2023. The rise in demand for rapid, efficient, saliva-based screening tests has positively impacted market growth.



This is primarily due to the various advantages offered by saliva-based tests, increasing product approvals by regulatory bodies, and a paradigm shift toward point-of-care testing. The fluorescence-labeled antigen/antibodies test is one of the recent saliva-based COVID-19 screening tests in the market which is based on the principles of fluorescence detection, biochemistry, robotics automation, and cloud computing.



As the number of people visiting public places is increasing and reaching pre-pandemic statistics in a few countries, there is a growing demand for rapid, point-of-care COVID-19 tests to mitigate viral transmission from asymptomatic people. This has enhanced the R&D for the development of simple yet effective saliva-based tests and is expected to create lucrative opportunities for several developers.



COVID-19 Saliva Screening Test Potential Market Report Highlights

  • The market estimates represent a potential market size for the COVID-19 saliva screening test based on the assumptions that the end-use locations have a 60% population attendance or capacity (60% of pre-COVID attendance) and the testing rate using test device is 100%
  • Saliva-based tests play a vital role in screening asymptomatic individuals thereby aiding in market revenue generation in the near future
  • The fluorescence-labeled antigen/antibodies test is designed to accelerate rapid point-of-access testing of individuals
  • Owing to the pandemic, the economy across the various sectors is severely impacted.
  • However, with the reopening of various sectors and locations such as shopping malls and amusement parks, there is a growing need for screening individuals to curb viral transmission
  • In the U.S., more than 40 amusement parks have prepared to reopen by the spring of 2021, thus increasing the demand for rapid tests
  • Thus, there is a high growth potential for the market with the increase in usage of the medical test at various locations to screen individuals
  • Regulatory bodies such as the U.S. FDA and European Medicine Agency (EMA) have supported these products by providing EUA and product approvals
  • In April 2021, Vatic Health received the CE mark for its on-the-spot’ saliva antigen test for the SARS-CoV-2 virus. The test has also completed the Medicines and Healthcare Products Regulatory Agency (MHRA) registration in the U.K.
  • North America dominated the market owing to the high penetration and adoption of saliva-based screening tests in the region
  • The U.S. is the major contributor to revenue generation due to the emergence of new small and mid-sized companies engaged in the development of such tests

Key Topics Covered:



Chapter 1 Methodology and Scope



Chapter 2 Executive Summary



Chapter 3 COVID-19 Saliva Screening Test Potential Market: Industry Outlook

3.1 Fluorescence-labeled antigen/antibodies testing: Opportunity Analysis

3.1.1 Competitive products analysis

3.1.1.1 Competitive analysis- COVID-19 POC testing

3.2 Market Dynamics

3.2.1 Market driver analysis

3.2.1.1 Advantages of using saliva as a diagnostic specimen

3.2.1.2 Increasing product approvals by regulatory agencies

3.2.1.3 Paradigm shift toward point-of-care testing

3.2.2 Market restraint analysis

3.2.2.1 High penetration of swab-based testing methods

3.2.2.2 Limitations related to the methodological approach

3.2.3 Market opportunity analysis

3.2.3.1 Safe, quick, and economical nature of saliva-based COVID-19 tests

3.2.4 Market challenge analysis

3.2.4.1 Challenges pertaining to COVID-19 testing in healthcare settings

3.3 Comparative Analysis

3.3.1 Saliva testing versus swab-based RT-PCR testing

3.3.1.1 Global swab-based COVID-19 Diagnostics market, 2020 – 2027 (USD Million)

3.3.2 Saliva testing versus other antigen testing

3.4 Competitive Analysis

3.4.1 Major deals &strategic alliances analysis

3.4.1.1 Technology collaboration & licensing partnership

3.4.1.2 Distribution partnership

3.4.2 Strategy framework

3.4.3 Company participant categorization

3.4.4 Product approval/EUA authorizations& launch timeline



Chapter 4 COVID-19 Saliva Screening Test Potential Market: Location Estimates & Trend Analysis (U.S. & Canada)

4.1 Travel Stations

4.1.1 Airports

4.1.2 Cruise

4.1.3 Port

4.1.4 Train stations

4.1.5 Border crossing

4.2 Sports Arenas

4.3 Concert Halls

4.4 Shopping Malls and Centers

4.5 Amusement Parks

4.6 Corporate Campus Environment

4.7 Universities and Colleges

4.8 Factories

4.8.1 Food processing plants

4.8.2 Meat packing plants

4.8.3 Pharmaceutical plants

4.8.4 Mining

4.8.5 Retail working warehouses



Chapter 5 COVID-19 Saliva Screening Test Potential Market: Location Estimates & Trend Analysis (Other Regions)

5.1 Travel Stations

5.2 Sport Arenas

5.3 Entertainment Venues

5.4 Corporate Environments

5.5 Universities & Colleges

5.6 Factories



Chapter 6 COVID-19 Saliva Screening Test Potential Market: Technology Estimates & Trend Analysis

6.1 COVID-19 Saliva Screening Market: Technology Movement Analysis

6.2 Fluorescence-labeled antigen/antibodies testing

6.2.1 Overview

6.2.2 Key strategic initiatives

6.3 RT-PCR

6.3.1 Technical viewpoint

6.3.2 Future potential

6.3.3 Commercial viewpoint

6.4 CRISPR-Cas9

6.4.1 Technical viewpoint

6.4.2 Future potential

6.4.3 Commercial viewpoint



Chapter 7 COVID-19 Saliva Screening Test Potential Market: Mode Estimates & Trend Analysis

7.1 COVID-19 Saliva Screening Test Potential Market: Mode Movement Analysis

7.2 Centralized Testing (Labs, Hospitals, Clinics)

7.3 Decentralized Testing (Mobile Testing, At-home Testing, Others)



Chapter 8 Regional Business Analysis

8.1 COVID-19 Saliva Screening Test Potential Market: Regional Movement Analysis, 2020 & 2023

8.2 North America

8.2.1 U.S.

8.2.2 Canada

8.3 Europe

8.4 Asia Pacific

8.5 Rest of the World



Chapter 9 Company Profiles

9.1 Company overview

9.2 Financial performance

9.3 Product benchmarking

9.4 Strategic initiatives

  • ARUP Laboratories.
  • Vatic Health
  • MOgene
  • Psomagen, INC.
  • DXTERITY Diagnostics, INC.
  • KONICA MINOLTA, INC.
  • Fluidigm Corporation
  • Phosphorus Diagnostics LLC
  • Gravity Diagnostics
  • OraSure Technologies
  • Quidel Corporation
  • ABBOTT

For more information about this report visit https://www.researchandmarkets.com/r/pas74i

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com   



For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



U.S. Fax: 646-607-1904

Fax (outside U.S.): +353-1-481-1716

Cision View original content:https://www.prnewswire.com/news-releases/global-covid-19-saliva-screening-test-market-report-2021-2023—increasing-product-approvals-by-regulatory-agencies–paradigm-shift-toward-point-of-care-testing-301371551.html

SOURCE Research and Markets